Definitive Contract 75A50124C00062
Award Date
9/30/24
Potential Completion Date
9/30/29
Potential Value
$226M
Awardee
Hopo Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
Q701 - Specialized Medical Support
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Berkeley, CA 94704, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a $10,299,171.18 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Humanetics Corp, a for-profit biopharmaceutical company. The contract is for an NHP (non-human primate) efficacy study of BIO 300, a therapeutic candidate being developed by Humanetics to mitigate radiation-induced pneumonitis and pulmonary fibrosis. This work builds on Humanetics' prior federal grants from agencies like NIH, DoD, and the Army for research and...
This is a definitive, cost-no-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cleveland Biolabs, Inc. to develop a therapy for hematopoietic syndrome resulting from acute radiation exposure. The contract, which does not have a set-aside designation, has a ceiling value of $21,956,799.00 and an ultimate completion date of October 15, 2010. As the prime contractor, Cleveland Biolabs, Inc. is responsible for delivering the...
<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>
This is a $100,361,311 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the non-profit research organization MRIGlobal, also known as Midwest Research Institute, for the development of "Biodosimetry High-Throughput Diagnostic Tests." The contract supports the creation of diagnostic tests to evaluate radiation exposure, which is a critical capability for public health emergency preparedness. As a prime contractor,...
This is a $36,967,744.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Asell, LLC for the advanced development, validation, and FDA clearance of the CellRadX point-of-care biodosimetry system. The contract is not set-aside. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for the advanced...
This is a $918,380,272.80 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Phlow Corp, a for-profit pharmaceutical manufacturing company, for the advanced manufacturing of COVID-19 essential medicines and future threats. The contract has a base period funding of May 18, 2020 through May 17, 2030. Phlow Corp has subcontracted with Virginia Commonwealth University, a...
<p>This is a federal contract award valued at $237,994,127.86, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Hoffmann-La Roche Inc. The contract is for the "COMBATING MULTI-DRUG RESISTANCE AND ADDRESSING EMERGING BACTERIAL THREATS: DISCOVERY, CLINICAL DEVEL" program, with a period of performance through September 30, 2027. The contract is a definitive, cost-no-fee contract and does not have a set-aside designation.</p>
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
This is a $65,806,649.98 cost-plus-fixed-fee definitive contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Biofactura Inc., a for-profit manufacturer located in Frederick, Maryland. The contract includes preclinical and manufacturing development activities such as cell line development, process development, non-clinical efficacy and safety studies, manufacturing, and clinical activities. The contract has an...